Induced Pluripotent Stem Cell-Derived Cardiomyocytes Therapy for Ischemic Heart Disease in Animal Model: A Meta-Analysis.
Quan Duy VoYukihiro SaitoKazufumi NakamuraToshihiro IidaShinsuke YuasaPublished in: International journal of molecular sciences (2024)
Ischemic heart disease (IHD) poses a significant challenge in cardiovascular health, with current treatments showing limited success. Induced pluripotent derived-cardiomyocyte (iPSC-CM) therapy within regenerative medicine offers potential for IHD patients, although its clinical impacts remain uncertain. This study utilizes meta-analysis to assess iPSC-CM outcomes in terms of efficacy and safety in IHD animal model studies. A meta-analysis encompassing PUBMED, ScienceDirect, Web of Science, and the Cochrane Library databases, from inception until October 2023, investigated iPSC therapy effects on cardiac function and safety outcomes. Among 51 eligible studies involving 1012 animals, despite substantial heterogeneity, the iPSC-CM transplantation improved left ventricular ejection fraction (LVEF) by 8.23% (95% CI, 7.15 to 9.32%; p < 0.001) compared to control groups. Additionally, cell-based treatment reduced the left ventricle fibrosis area and showed a tendency to reduce left ventricular end-systolic volume (LVESV) and end-diastolic volume (LVEDV). No significant differences emerged in mortality and arrhythmia risk between iPSC-CM treatment and control groups. In conclusion, this meta-analysis indicates iPSC-CM therapy's promise as a safe and beneficial intervention for enhancing heart function in IHD. However, due to observed heterogeneity, the efficacy of this treatment must be further explored through large randomized controlled trials based on rigorous research design.
Keyphrases
- ejection fraction
- left ventricular
- systematic review
- aortic stenosis
- heart failure
- randomized controlled trial
- high glucose
- blood pressure
- single cell
- case control
- end stage renal disease
- induced pluripotent stem cells
- acute myocardial infarction
- risk factors
- public health
- chronic kidney disease
- oxidative stress
- newly diagnosed
- cell therapy
- stem cells
- meta analyses
- risk assessment
- diabetic rats
- big data
- mesenchymal stem cells
- combination therapy
- weight loss
- bone marrow
- human health
- mass spectrometry
- climate change
- high resolution
- peritoneal dialysis
- atrial fibrillation